Search / Trial NCT06613204

STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners

Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Sep 23, 2024

Trial Information

Current as of December 21, 2024

Not yet recruiting

Keywords

Behavioral Intervention Ftd

ClinConnect Summary

The study will enroll a total sample of up to 640 participants: 320 family care partners and their 320 care Recipients with FTD. For our study "family Care Partner" includes any person who is considered "family" to the person with FTD, such as direct relations, fictive kin, close friends and neighbors. "Care Recipient" is defined as an individual with an FTD diagnosis noted by the AFTD: bv-FTD, PPA, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or ALS with FTD. Care Recipients with FTD will not participate in intervention but will be consented (and thus enrolled) be...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria: Family Care Partner
  • Adult caring for family member with FTD.
  • Provides 4 or more hours of care/week. Does not have to reside with.
  • Identifies at least 2 moderately upsetting behaviors in the person with FTD.
  • Speaks and understands English to be able to participate in intervention.
  • Owns a telephone (smartphone, cell phone or landline).
  • Has email and mailing address to receive computer, study materials and surveys.
  • Provides informed consent to participate in the research.
  • Lives in the US
  • Inclusion Criteria: Person with FTD
  • Diagnosis of FTD
  • Family member of a Care Partner (this can be a relative, spouse, or close kin that is considered family).
  • Lives in US
  • Exclusion Criteria: Person with FTD
  • No Frontotemporal Degeneration diagnosis.
  • Unable to leave Care Partner during STELLA-FTD sessions.
  • Enrolled in hospice.
  • Exclusion Criteria: Family Care Partner
  • Unable to find activity for Care Recipient during STELLA-FTD sessions to allow Care Partner to work privately with Guide and other Care Partners.
  • Hearing and/or vision problems severe enough to prevent participation.
  • Refuses to be video-recorded during STELLA-FTD sessions.
  • Unwilling or unable to adequately follow study instructions and participate in study procedures.

Trial Officials

Allison Lindauer, PhD, APRN

Principal Investigator

Oregon Health & Science University

Aimee Mooney, MA, CCC-SLP

Study Director

Oregon Health & Science University

About Oregon Health And Science University

Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0